Evidence map›Paper›PMID 30779592›Full record

ReviewArchives of pathology & laboratory medicine2019

High-Grade Sinonasal Carcinoma: Classification Through Molecular Profiling.

Julie Guilmette, Peter M Sadow

Open access · diamondAbstract readReview
In one paragraph

Review in Archives of pathology & laboratory medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Molecular Evidence for Olfactory Neuroblastoma as a Tumor of Malignant Globose Basal Cells.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2023
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Julie GuilmetteFrom the Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston.
Peter M SadowFrom the Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston.
Massachusetts General Hospital · US

Funding

Strategies to Overcome Immune Resistance in Head and Neck CancersP01CA240239 · NCI · YALE UNIVERSITY · PI SARTOR, MAUREEN AGNES · 2019 to 2023
$8.4M
NCI NIH HHS P01 CA240239
6 · The paper itself

Abstract

High-grade sinonasal carcinomas are a cohort of malignant epithelial neoplasms arising in the sinonasal cavities with distinct, ominous morphologic features or lacking well-differentiated features that might otherwise classify them as less biologically worrisome. Recent advances in molecular profiling have led to the identification of several distinct tumor entities previously grouped together. These molecularly distinct lesions include

Indexed as

Bromodomain Containing ProteinsCarcinomaCell Cycle ProteinsDNA HelicasesGene FusionHumansMaxillary Sinus NeoplasmsMutationNeoplasm GradingNeoplasm ProteinsNuclear ProteinsOncogene ProteinsParanasal SinusesParanasal Sinus NeoplasmsSMARCB1 ProteinTranscription FactorsBRD4 protein, humanBromodomain Containing ProteinsCell Cycle ProteinsDNA HelicasesNeoplasm ProteinsNuclear ProteinsNUTM1 protein, humanOncogene ProteinsSMARCA4 protein, humanSMARCB1 ProteinSMARCB1 protein, humanTranscription Factors

Identifiers

PMID30779592
PMCPMC7405598
OpenAlexW2917495415

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.